Form D · Biotechnology
SURGE Therapeutics, Inc.
Cambridge, MA · CIK 0001834664
Offering snapshot reported Jun 2, 2023 · SEC filing
- Reported sold
- $32M Offering amount: $50M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 19, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 2, 2023 | Initial | $32,003,969 | No comparison | 22 | SEC filing |
| Dec 4, 2020 | Initial | $20,634,443 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-483195
Source: Form D, filed Jun 2, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Chuck Carignan | Executive |
| Jason Coloma | Director |
| Ali Farahanchi | Director |
| Michael S. Goldberg | Director, Executive |
| Gary Goldberg | Director |
| Antonio Gualberto | Executive |
| Kouki Harasaki | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Broadway, 14 Th Floor
Cambridge, MA, 02142
Cambridge, MA, 02142